ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 614.5 DKK | -0.41% |
|
+2.42% | +64.66% |
| Sales 2024 * | 441M 64.17M | Sales 2025 * | 1.02B 148M | Capitalization | 38.28B 5.57B |
|---|---|---|---|---|---|
| Net income 2024 * | -653M -95.06M | Net income 2025 * | -399M -58.08M | EV / Sales 2024 * | 81.5 x |
| Net cash position 2024 * | 2.37B 345M | Net cash position 2025 * | 2.44B 355M | EV / Sales 2025 * | 35.2 x |
| P/E ratio 2024 * |
-61.5
x | P/E ratio 2025 * |
-64.7
x | Employees | 270 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zealand Pharma A/S
More press releases
More news
| 1 day | -0.41% | ||
| 1 week | +2.42% | ||
| Current month | -2.92% | ||
| 1 month | -1.21% | ||
| 3 months | -0.89% | ||
| 6 months | +91.91% | ||
| Current year | +64.66% |
1 week
560.00
630.50
1 month
560.00675.00
Current year
342.20749.00
1 year
212.20749.00
3 years
69.55749.00
5 years
69.55749.00
10 years
58.00749.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 09-12-31 | |
| Director of Finance/CFO | - | 22-10-31 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 19-04-03 |
| Chairman | 69 | 14-12-31 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18-04-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 614.5 | -0.41% | 237,079 |
| 24-05-27 | 617 | +5.20% | 303,643 |
| 24-05-24 | 586.5 | -2.74% | 482,108 |
| 24-05-23 | 603 | -1.71% | 234,630 |
| 24-05-22 | 613.5 | -1.45% | 173,087 |
Delayed Quote Nasdaq Copenhagen, May 28, 2024 at 10:59 am EDT
More quotes
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-08-15
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
614.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+27.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +64.66% | 5.59B | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
- Stock Market
- Equities
- ZEAL Stock
